We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder

Embryology

House of Lords written question – answered on 12th December 2011.

Alert me about debates like this

Photo of Lord Alton of Liverpool Lord Alton of Liverpool Crossbench

To ask Her Majesty's Government, further to the Written Answer by Earl Howe on 5 December (WA 114-15), whether the proposed clinical trial at Moorfields Eye Hospital will also employ retinal pigmented epithelial (RPE) cells generated by direct reprogramming of other adult cell types, described by Sir Ian Wilmut as avoiding risks of tumorigenesis associated with a pluripotent stage; and whether the RPE cells to be used in the trial or the embryonic cells from which they were derived have been regularly tested to ensure that they do not also exhibit chromosomal alterations in culture.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

The product to be used in the clinical trial at Moorfields Eye Hospital does not employ retinal pigmented epithelial cells generated by direct reprogramming of other adult cell types.

Testing is undertaken to ensure that chromosomal alterations during culture do not occur.

Details of these tests are commercially confidential and therefore we are unable to reveal them.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.